Updated Guidelines for the Use of Rifabutin or Rifampin in HIV-Infected Patients Receiving Antiretroviral Agents
[MMWR 2000;49:185]

These are updated CDC recommendations for the use of rifabutin or rifampin with PIs or NNRTIs. The concern is for drug interactions resulting from the activity of these agents with the cytochrome P-450 isoenzymes. Rifamycins induce CYP450. PIs inhibit CYP450 and NNRTIs are variable. The new data indicate that rifampin, previously considered contraindicated with any PI or NNRTI, can now be used with efavirenz, ritonavir, or ritonavir plus saquinavir (HGC or SGC). Rifabutin may be given with most of the PIs and NNRTIs, but the dose usually should be decreased, and it should be increased when given with efavirenz. The full listing of recommendations are summarized in the table below: JGB, 5/8/2000

Recommendations for Co-Administration of Antiretroviral Agents and Rifabutin or Rifampin